Industry Insight
Discovery Technology
Analytical Laboratory Technology
Biopharma
Manufacturing
Delivery Systems
Ingredients, Formulation and Finishing
Bioprocessing
View our other publications with free access to extensive archives
  To print this article:
Existing subscribers please log in:
 
  USER NAME  
  PASSWORD  
   Or select

Or become a subscriber
 
 
 

The use of surrogate markers to accelerate develop

Four case studies reflect the importance of technique, precision and interpretation when choosing and applying surrogate markers in clinical drug development.

Dr Kenneth Faulkner and Dr Charles Peterfy, Synarc (June 2000)

Keywords: clinical research, clinical trial supplies, post-marketing surveillance, regulatory and approval services, regulatory data, drug patent, drug registration, Synarc, surrogate markers,

    View full article    |    Back to Discovery Technology section




Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPTonline © 2004 The Pharmaceutical Technology Journal | Terms and Conditions | info@iptonline.com | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |